Key result
No clinical data or findings are present in the provided text, which consists only of journal editorial board information.
Why the study?
Do ex vivo additions of PCC, FEIBA, or rVIIa reverse the anticoagulant effects of dabigatran and rivaroxaban on thrombin generation assays?
Population
32 patients, comprising 17 receiving dabigatran 150 mg twice daily for non-valvular atrial fibrillation and…
Comparison
Ex vivo addition of prothrombin complex… vs Baseline patient blood and plasma samples.
Design
Other
Authors
Loading...
No clinical data provided; leaves open whether PCC, FEIBA, or rVIIa reverse dabigatran and rivaroxaban on thrombin generation.
Do ex vivo additions of PCC, FEIBA, or rVIIa reverse the anticoagulant effects of dabigatran and rivaroxaban on thrombin generation assays?
Ex vivo testing suggests that PCC and FEIBA can effectively reverse the anticoagulant effects of dabigatran and rivaroxaban on thrombin generation.
Thom et al. (2013) studied this question. No clinical data or findings are present in the provided text, which consists only of journal editorial board information.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: